BARACLUDE(R) (entecavir) Approved By The European Commission For The Treatment Of Chronic Hepatitis B In Adult Patients
Links shared publicly online about this topic.
- 469total visits
BARACLUDE(R) (entecavir) Approved By The European Commission For The Treatment Of Chronic Hepatitis B In Adult Patients
Bristol-Myers Squibb (NYSE: BMY) announced that BARACLUDE(R) (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients wit
View full resource at medicalnewstoday.com
Tags: Liver Condition, Hepatitis, Hepatitis B, Hepatitis B Medication, Baraclude, Bristol-Myers Squibb
Most Recently Shared on March 2, 2011 at 12:05 pm By:
BARACLUDE(R) (entecavir) Approved By The European Commission For The Treatment Of Chronic Hepatitis B In Adult Patients http://mnt.to/3RLW
Also Shared By:
BARACLUDE(R) (Entecavir) Approved By The European Commission For The Treatment Of CHB In Adult Patients With Evidence Of Decompensated Liver Disease
medicalnewstoday.com — “Bristol-Myers Squibb (NYSE:BMY) announced that BARACLUDE® (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients wi” View full resource at medicalnewstoday.com
Most Recently Shared on March 2, 2011 at 9:05 am By:
BARACLUDE(R) (Entecavir) Approved By The European Commission For The Treatment Of CHB In Adult Patients With Evidence ... http://mnt.to/3RKX
Advertisement
MNT Liver Disease
@mnt_liver
BARACLUDE(R) (Entecavir) Approved By The European Commission For The Treatment Of CHB In Adult Patients With Evidence ... http://mnt.to/3RKX
1 year ago...